Document is current
Any future updates will be listed below
-
Authors
Bai, Baoyan https://orcid.org/0000-0001-7017-4442
Wise, Jillian F.
Vodák, Daniel
Nakken, Sigve https://orcid.org/0000-0001-8468-2050
Sharma, Ankush https://orcid.org/0000-0002-1399-7503
Blaker, Yngvild Nuvin
Brodtkorb, Marianne
Hilden, Vera
Trøen, Gunhild
Ren, Weicheng
Lorenz, Susanne
Lawrence, Michael S.
Myklebost, Ola https://orcid.org/0000-0002-2866-3223
Kimby, Eva https://orcid.org/0000-0003-3078-6131
Pan-Hammarström, Qiang https://orcid.org/0000-0003-1990-8804
Steen, Chloé B.
Meza-Zepeda, Leonardo A.
Beiske, Klaus
Smeland, Erlend B.
Hovig, Eivind https://orcid.org/0000-0002-9103-1077
Lingjærde, Ole Christian https://orcid.org/0000-0003-3565-4912
Holte, Harald https://orcid.org/0000-0001-9799-9428
Myklebust, June Helen https://orcid.org/0000-0003-0394-9986
- License Information
-
More Information
Article History
Received: 19 January 2024
Revised: 2 August 2024
Accepted: 9 August 2024
First Online: 27 August 2024
Competing interests
: EK has served on the advisory boards of Celgene, Janssen and AbbVie, and has provided educational lectures for Celgene, Janssen, AbbVie and Astra Zeneca. OCL has served as a statistical advisor for Novartis and provided educational lectures for Nykode Therapeutics. HH has served on the advisory boards of Roche, Celgene, Nordic Nanovector, Novartis and Takeda and has provided educational lectures for Novartis. EBS owns stock in Nordic Nanovector and is a named inventor on a patent filed by the National Cancer Institute: “Methods for selecting and treating lymphoma types” licensed to NanoString Technologies; named inventor on a patent: “Evaluation of mantle cell lymphoma and methods related thereof.” All other authors declare no competing interest.
